Flush with cash from their GLP-1 franchises, Eli Lilly and Novo Holdings have become the most active participants in Series A biotech funding. They are leveraging their deep pockets to stimulate company formation and strategically branch into new therapeutic areas, shaping the next wave of innovation.

With a market cap driven by its obesity drugs, Eli Lilly is making multi-billion dollar acquisitions like Centessa that are mere "rounding errors" for its finances. This strategy allows it to buy into high-potential, next-generation therapeutic areas like the orexin space for a relatively low financial risk, diversifying beyond GLP-1s.

Eli Lilly's deal chief revealed that even premium acquisition offers are frequently rebuffed by public biotech companies without negotiation. This highlights a significant valuation gap where biotech boards believe their assets are worth far more than what even well-capitalized buyers like Lilly are willing to pay, stalling potential M&A activity.

Major pharmaceutical companies are committing to bio-buck deals worth billions for unproven, preclinical assets. The Sanofi-Irindale deal ($2.56B potential) and the Pfizer-Cartography deal ($850M+ potential) for discovery-stage programs show a high appetite for risk when accessing innovative technology platforms and novel targets early on.

After years of focusing on de-risked late-stage products, the M&A market is showing a renewed appetite for risk. Recent large deals for early-stage and platform companies signal a return to an era where buyers gamble on foundational science.

Eli Lilly's recent deal-making reveals an aggressive, multi-modal strategy. It secured an AI partnership for obesity (Nimbus), invested in an AI platform for oncology (InduPro), and spent $1.2B acquiring Ventix Biosciences for its oral inflammation pipeline, demonstrating a broad approach to securing leadership in its focus areas.

Gilead's acquisition of Arcellx includes a CVR, promising an extra $5 per share if the drug anita-cel hits a $6B sales target by 2029. This structure mitigates upfront risk for Gilead while allowing Arcellx shareholders to benefit from future commercial success, aligning incentives post-acquisition.

The acquisition of Verona shows that a novel mechanism of action with a substantial clinical effect can make a company a prime M&A target. This holds true even with weaknesses like no composition of matter patent or an unfashionable drug delivery method, especially in disease areas lacking innovation.

When comparing drugs with the same mechanism, like Alkermes' and Takeda's orexin agonists, a wider therapeutic index is a crucial differentiator. This superior safety-to-efficacy ratio allows for higher, more effective dosing without significant side effects, creating a competitive advantage and potential for broader market use.